China OKs Lynparza as Maintenance Therapy for Advanced Ovarian Cancers with BRCA Mutations

China OKs Lynparza as Maintenance Therapy for Advanced Ovarian Cancers with BRCA Mutations
Oral Lynparza (olaparib) has been approved in China as a first-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer who responded to initial platinum-based chemotherapy, AstraZeneca and Merck (known as MSD outside the U.S. and Canada) announced. Lynparza is now the first PARP enzyme inhibitor approved in that country as an initial maintenance treatment for BRCA-mutated advanced ovarian cancer. Similar approvals have been granted in the U.S.Europe, Canada, Brazil and Japan. “This approval marks a new era for women with BRCA-mutated advanced ovarian cancer in China, where the prevalence of BRCA mutations in advanced disease is higher than the international average,” Dave Fredrickson, executive vice president, oncology business unit, AstraZeneca, said in a press release. This oral anti-cancer treatment works by blocking the PARP enzyme, which is involved in DNA repair and cancer cell survival and proliferation. It has been found to be particularly effective in pat
Subscribe or to access all post and page content.